CASE CCC IN THE NEWS
ASPO Annual Meeting Showcases Innovative Approaches to Cancer Prevention
Oncology Times - Mar 27, 2014
Science, policy, and legislation are combining to foster progress in cancer prevention. That was the word from speakers here at the American Society of Preventive Oncology (ASPO) Annual Meeting...In addition to cutting-edge new science, the meeting also featured presentations on lifestyle behaviors such as smoking and physical activity. The following are some of the highlights of the research presented. Retinol-Binding Protein 4 & Risk of Colon Adenoma: A study believed to be the first of its kind showed that higher circulating levels of serum retinol-binding protein 4 (RBP4), a recently discovered biomarker of insulin resistance, are associated with a risk of colon adenoma --especially and surprisingly among those with a lower body mass index (BMI). Insulin resistance is believed to be a key linking obesity to colon cancer, said study co-author Li Li, MD, PhD, Associate Director for Prevention Research at the Case Comprehensive Cancer Center and Professor of Family Medicine at Case Western Reserve University
Reassurance from Large Study that Contrary to Earlier Thinking, Prostate Cancer Patients Receiving Radiation Do Not Have Increased Risk of MDS
Oncology Times - Mar 25, 2014
Men who receive radiation treatment for prostate cancer are at no greater risk for developing myelodysplastic syndromes (MDS) than the general population, according to a study now available online ahead of print in the Journal of the National Cancer Institute. Common thinking, passed down to oncologists and largely from review articles, has been that patients exposed to radiation or any type of chemotherapy who then develop MDS have therapy-related MDS, said Mikkael A. Sekeres, MD, MS, senior author of the study and Director of the Leukemia Program at Cleveland Clinic's Taussig Cancer Institute.
AACR Annual Meeting
The American Association for Cancer Research (AACR) Annual Meeting will take place April 5-9 in San Diego. The Case CCC has many members participating in the meeting.
As was highlighted in last week's newsletter, we are especially pleased that two of our members, Drs. Charis Eng and Nima Sharifi have been recognized with awards and will be presenting lectures; what an honor! In addition,Dr. Neal Meropol will give a presentation on clinical trials funding; Dr. Yiping Han will speak about oral bacteria and colorectal cancer; and Dr. Lyndsay Harris will present on genomic markers and breast cancer.
The research of many of our members will also be highlighted at mini-symposiums and poster presentations. We wish all of you the best of luck! A full list of Cancer Center presentations is posted on the Cancer Center website.
2014 Affymetrix® Tumor Profiling Grant Program
The 2014 Affymetrix® Tumor Profiling Grant Program is designed to support translational cancer researchers who are discovering and validating biomarkers to address an unmet clinical need by combining multiple omics data. Affymetrix will support up to three grants globally with reagents to profile up to 30 samples.
Deadline: April 15
Dr. Marty Veigl, Director of the Gene Expression & Genotyping Core Facility is available to assist anyone who may need information to put together their proposal.
Request for Proposals for Case CCC Funding for Pilot/Phase I Clinical Trials
The Case CCC is encouraging investigators to submit Letters of Intent (LOI) for Early Phase Clinical Research Support (EPCRS) funding. These in-house funds are available for the conduct of early phase clinical trials of relatively short duration. Priority will be given to trials which are developed jointly between UH and CCF with planned accrual at both institutions. (See revised NCI Cancer Center Support Grant EPCRS guidelines, page 43, Section 2.12). Please submit LOIs to Katarzyna Karelus, Case CCC Clinical Research Office, firstname.lastname@example.org, 216.844.4176.
LOI deadline: April 15
DoD Breast Cancer Research Program
The Fiscal Year 2014 (FY14) Defense Appropriations Act provides $120 million (M) to the Department of Defense Breast Cancer Research Program (BCRP) to support innovative, high-impact breast cancer research.
The Breast Cancer Breakthrough Award Levels 1 and 2 supports promising research that has high potential to lead to or make breakthroughs in breast cancer. Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must be significant and move beyond an incremental advancement. Two different funding levels, based on the scope of the research, are available under this Program Announcement.
Deadline: May 28
The Breast Cancer Breakthrough Award Levels 3 and 4 supports promising research that has high potential to lead to or make breakthroughs in breast cancer. Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must be significant and move beyond an incremental advancement. Two different funding levels, based on the scope of the research, are available under this Program Announcement.
Deadline: May 28
The Breast Cancer Innovator Award supports visionary individuals who have demonstrated creativity, innovative work, and leadership in any field including, but not limited to, breast cancer. The Innovator Award will provide these individuals with the funding and freedom to pursue their most novel, visionary, high-risk ideas that could ultimately lead to ending breast cancer.
Deadline: August 15
The Breast Cancer Era of Hope Scholar Award supports individuals who are early in their careers and have demonstrated significant potential for innovation in breast cancer research. These individuals should be exceptionally talented scientists who have shown that they are the "best and brightest" in their field(s) through extraordinary creativity, vision, and productivity. They should have demonstrated experience in forming effective partnerships and collaborations and should exhibit strong potential for leadership in the breast cancer research community.
Deadline: August 15
DoD Bone Marrow Failure Research Program
The FY14 Defense Appropriations Act provides $3.2 million (M) to the Department of Defense Bone Marrow Failure Research Program (BMFRP) to support innovative research committed to advancing the understanding of inherited and acquired bone marrow failure diseases.
The BMFRP Idea Development Award is intended to support innovative ideas and high-impact approaches based on scientifically sound evidence to move toward the BMFRP vision of understanding and curing BMF diseases. This award mechanism is designed to support new ideas. Proposed research studies should have a high probability of revealing new avenues of investigation. Research projects should include a well-formulated, testable hypothesis based on strong scientific rationale and a developed and well-articulated research approach. Personnel on the proposed team should have a strong background in BMF research.
Deadline: August 28
MARK YOUR CALENDARS
GI SPORE Retreat
Registration is open for the Case Gastrointestinal Cancers SPORE Retreat, April 24 in Dively Rm. 202. Planned presentation topics include: Colon Cancer, Barrett's Esophagus, Cancer Metastasis, Cancer Prevention, and Cancer in Minorities.
The day will also feature poster presentations by trainees and fellows. To participate, submit abstracts to John Wang (email@example.com) by April 17.
Screening for Cancer in Women: 2014
Register today for Screening for Cancer in Women: 2014, Wednesday, May 21 from 8 am - 3:35 pm at the Embassy Suites Hotel in Independence.
Optimal strategies in cancer screening and detection are constantly evolving, and best practices are changing. This conference will feature speakers from health centers across Northeast Ohio working together to fight cancer, who will offer expert insight, updates, and advice on screening for cancer in women.
This comprehensive symposium is aimed at primary care providers and cancer specialists with updates that can be incorporated into their practices:
- New screening technologies, particularly to detect breast and lung cancer
- Current guidelines for colorectal, skin, lung, breast, and cervical cancer screening
- Impact of the Affordable Care Act
- Racial and economic disparities within cancer screening and detection
- When to refer a patient for a genetics referral or to a high-risk clinic
CME credit will be offered. Visit the conference website for more details and registration information.